Your search history is turned on.
Date: April 10, 2024 Jurisdictions: Alberta, British Columbia, Ontario
WPD PHARMACEUTICALS INC. STATEMENT OF EXECUTIVE COMPENSATION For the Years Ended December 31, 2022 and 2021 (Expressed in Canadian Dollars) WPD Pharmaceuticals Inc. (the "Company") is a 'venture issuer' and is disclosing the compensation of its named executive officers and directors ...
FORM 51-102F3 MATERIAL CHANGE REPORT Item 1 Name and Address of Company WPD Pharmaceuticals Inc. (the Company) 750 West Pender Street, Suite 401 Vancouver, BC V6C 2T7 Item 2 Date of Material Change April 22, 2022 Item 3 News Release The news release attached as Schedule A announcing the material changes described i...
Date: February 7, 2024 Jurisdictions: Alberta, British Columbia, Ontario
FORM 51-102F3 Material Change Report Item 1. Name and Address of Company WPD Pharmaceuticals Inc.(the "Company") 750 Pender Street West #401 Vancouver, BC V6C 2T7 Item 2. Dates of Material Change November and December 2023 and January 2024 Item 3. News Release A news release dated January 31, 2024 was disseminated with Stockwatch and Baystreet...
Date: February 5, 2024 Jurisdictions: Alberta, British Columbia, Ontario
Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate I, Mariusz Olejniczak, Chief Executive Officer of WPD Pharmaceuticals Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of WPD Pharmaceuticals Inc. (the ...
Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate I, Mariusz Olejniczak, Acting Chief Financial Officer of WPD Pharmaceuticals Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of WPD Pharmaceuti...
WPD Pharmaceuticals Inc. Managements Discussion & Analysis For the Nine Months Ended September 30, 2023 and 2022 (Expressed in Canadian Dollars) WPD Pharmaceuticals Inc. Managements Discussion & Analysis For the Nine Months Ended September 30, 2023 an...
WPD Pharmaceuticals Inc. Condensed Interim Financial Statements For the nine months ended September 30, 2023 and 2022 (Expressed in Canadian Dollars) (Unaudited Prepared by Management) Page | 2 ...
Date: February 2, 2024 Jurisdictions: Alberta, British Columbia, Ontario
Microsoft Word - IFRS52109FV2 - 2023Q2 - CEO(12812239.2) NOTE TO READER In contrast to the certificate required for non-venture issuers under National Instrument 52-109 Certification of Disclosure in Issuers Annual and Interim Filings (NI 52-109), this Venture Issuer Basic Certificate does not include represe...
NOTE TO READER In contrast to the certificate required for non-venture issuers under National Instrument 52-109 Certification of Disclosure in Issuers Annual and Interim Filings (NI 52-109), this ...
WPD Pharmaceuticals Inc. Managements Discussion & Analysis For the Six Months Ended June 30, 2023 and 2022 (Expressed in Canadian Dollars) WPD Pharmaceuticals Inc. Managements Discussion & Analysis For the Six Months Ended June 30, 2023 and 2022 ...